Introduction
In New Zealand (NZ), the planning, purchasing and provision of health services is largely delegated to 20 geographically defi ned District Health Boards (DHBs). 1 Th irty-one Primary Health Organisations (PHOs), funded by DHBs, deliver primary health-care services to their enrolled populations, primarily through general practices. 2 Most 160 J OURNAL OF PRIMARY HEALTH CARE practicing pharmacists in NZ work in community pharmacies (78%), followed by hospital pharmacy (13%). 3 Historically, the way community pharmacy services have been contracted and funded has resulted in community pharmacists being isolated from other primary health-care providers. Th e revised 2016 New Zealand Health Strategy promotes the integration of services across the health sector. 4 Th e Ministry of Health's Pharmacy Action Plan 2016 to 2020 also gives a clear direction to recognise and promote the role of pharmacists as medicines experts. 5 Medication errors in primary care are a global issue, 6 -9 with one English study fi nding 1 in 20 prescriptions written by general practitioners (GPs) contained an error, and 1 in 550 contained a serious error. 9 Given 45.8 million funded prescriptions were dispensed in NZ in 2018, 10 there is potential for substantial harm to occur. Furthermore, international studies suggest 6-7% of hospital admissions are medication related, with over two-thirds of these presumed avoidable and potentially due to errors. 11 -13 A NZ study conducted between 2013 and 2015 estimated that 28% of hospital patients experienced one or more episodes of medication-related harm, with 29% of these originating in the community and precipitating an admission.
14 Pharmacist-led interventions in primary care may contribute to reducing medication-related adverse eff ects and hospital admissions, 15 , 16 in particular, by integrating pharmacists into general practice. 17 A large-scale, pharmacist-led intervention in English general practices was eff ective in reducing a range of medication errors. 18 Meta-analyses have also identifi ed signifi cant improvements in various chronic disease states, including hypertension, diabetes, hyperlipidaemia and overall cardiovascular risk, as a result of pharmacist interventions within general practices. 19 Integrating more pharmacists into general practice may also mitigate workforce shortages, noting that 27% of GPs and 17% of nurses in NZ intend to retire within 5 years. 20 , 21 Pharmacist integration into general practice is gaining momentum internationally, specifi cally in England, 22 , 23 Australia, 24 , 25 Canada, 26 and the US. 27 , 28 Aft er committing to invest £143 million to recruit 2000 pharmacists into general practice by 2020-21, 23 , 29 NHS England has recently announced that the new contract for general practice includes recurrent funding for 70% of the employment costs for practice pharmacists. 22 In NZ, the integration of pharmacists into general practice appears to be in its infancy. 30 -32 Little has been published about pharmacists working in general practice in NZ, beyond a 2017 study reporting 31 pharmacists working in this setting. 33 Th erefore, the aim of this research was to characterise pharmacist integration into general practice in NZ.
Methods
An online questionnaire was created to address the research aims. Pharmacists eligible to complete the survey:
deliver [ed] professional services from or within a general practice medical centre with a coordinated, collaborative and integrated approach with an overall goal to improve the quality use of medicines of the practice population . 34 Th e content of the questionnaire was informed by international literature, 34 , 35 expert advisors and the research team's experience as pharmacists. A series of items using Likert scale responses was adapted from a tool developed to assess how working in
WHAT GAP THIS FILLS
What is already known: Pharmacist integration into general practice is attracting attention internationally. Hawke's Bay, Waikato, Otago and Southland regions of New Zealand have invested in having pharmacists integrated into general practice. Economic benefi ts attributed to practice pharmacists have been savings in medication costs and freeing up general practitioner time, alongside improvements to the quality of patient care in terms of reduced medication errors and improvements in chronic disease management.
What this research adds: Pharmacists working in general practices in New Zealand appear concentrated in certain regions. Pharmacists are performing patient-facing roles, quality improvement roles and roles aimed at improving practice effi ciencies. In the absence of a guiding framework, various funding and employment models have emerged, but funding constraints are reported to be a major barrier to further expansion. Pharmacists responding to the questionnaire generally had a positive view of the role. One month later, all PHO chief executive offi cers were asked to invite pharmacists working in their PHOs to participate in the study. Supervisor and advisor contacts were asked to help with recruitment, and all pharmacists were asked to forward on the participation request to other pharmacists working in general practice.
Data were analysed using IBM SPSS Statistics 25 (IBM Corp, Armonk, NY, USA). 37 Percentages were rounded to two signifi cant fi gures.
Where possible, open-ended responses were categorised into nominal values for analysis. NVivo 11 soft ware (QSR International, Melbourne, Vic, Australia) 38 was used to facilitate the thematic analysis of free-text responses.
Ethical approval was obtained from the University of Auckland Human Participants Ethics Committee (Reference number 020302).
Results
Forty-nine responses were recorded: 36 completed or partially completed questionnaires met the inclusion criteria and were included in the analysis.
Pharmacist demographics
Most respondents were female, and 47% were aged 40-49 years (range 27-66 years). Twenty-nine pharmacists (81%) were at least 10 years postregistration (see Table 1 ). Table 2 shows quali fi cations held by practice pharmacists. All respondents had completed clinical postgraduate study, and only one had not completed postgraduate study in clinical pharmacy.
Location and practice characteristics Figure 1 highlights where practice pharmacists are working in NZ. Most respondents worked in North Island general practices ( n = 25), most commonly in the Hawke's Bay ( n = 8) or Wellington ( n = 7) regions. Four of the six South Island respondents worked in the Otago region.
Responding pharmacists worked in 104 general practices, with 74 of these practices being in the North Island. Th e time spent in each practice varied from 2 to 43 h per week. Twenty-one respondents (66%) worked in general practice full-time (≥30 h per week). 39 Th e mean (± s.d.) time spent working in general practice per week was 24.8 ± 10.7 h. One pharmacist worked across 29 practices, but the remainder worked in fi ve or fewer practices. Fourteen respondents worked in one practice only and, of these, fi ve worked fulltime in that practice. Th e number of enrolled patients in each practice varied from 600 to 28 000 (median 7400 interquartile range (IQR) 4039-12 000). Table 3 illustrates where practice pharmacists had worked previously. Most respondents had experience working in more than one setting, with 13 (36%) having worked in both community and hospital pharmacy, 4 (11%) having worked in both hospital pharmacy and PHOs and 11 (31%) having worked in community pharmacy, hospital pharmacy and PHOs. Some pharmacists had worked elsewhere, such as for government agencies and non-governmental organisations.
Employment and funding
Analyses from this point onwards were derived from 35 respondents (as one exited the questionnaire here), of whom 12 (34%) were concurrently employed in other areas. Five were also employed in community pharmacy, two in hospital pharmacy, four as independent consultants and six in other areas, including mobile medicines therapy assessment and locum work. Th e most common sole employers were PHOs ( n = 18; 51%), followed by DHBs ( n = 7; 20%). Th ree pharmacists were employed directly by practices, one by a community pharmacy, and three were independent contractors. Four respondents had a mixed employment model, being employed by a variety of employers including practices, DHBs and/or PHOs. Th e median time that respondents had been working in their current positions was two years and fi ve months (IQR 1.25-4.67 years). Table 4 highlights the sources of funding for the practice pharmacist positions. Th e general practice pharmacist position was most commonly funded by either DHBs ( n = 14 40%) or PHOs ( n = 12 34%). Four pharmacists were funded directly by practices, and fi ve had a mixed funding model.
Roles
Th ere was large variation in the number of patients seen each week (median 7 patients; IQR 3.5-20 patients). Table 5 lists the various roles practice pharmacists held within their practices. All seven respondents who were qualifi ed as pharmacist prescribers were prescribing for patients with various long-term conditions in their practices, including cardiovascular disease and risk reduction, gout, diabetes, chronic pain, arthritis and chronic obstructive pulmonary disease. One pharmacist was responsible for hepatitis C prescribing.
Of the pharmacists who were not prescribers, 16 (57%) believed being able to prescribe would benefi t their practice and 12 (43%) were unsure.
Examples of audits completed by pharmacists included high-risk medicines, such as lithium or anticoagulants, as well as monitoring targets for medicines (eg urate levels with allopurinol use) and bpac nz audits.
Changes to practice
All respondents felt that since working in general practice their access to patients' clinical information, communication with GPs, and rapport with GPs had increased or greatly increased. Most respondents also reported this for their application of pharmaceutical knowledge ( n = 30; 94%), interdisciplinary collaboration ( n = 27; 84%) and job satisfaction ( n = 30; 94%). Further changes are listed in Table 6 .
Benefi ts and challenges of integration and collaboration
Th e benefi ts and challenges of integration and collaboration are listed in Table 7 . For several respondents, funding was the main limiting factor. Some perceived a lack of understanding about the value and scope of practice pharmacists. Th is, along with the lack of existing relationships and rapport with practice staff , meant that the initial integration process was challenging for several pharmacists. However, some respondents reported that, as trusting and collaborative relationships developed, they became valued members of the practice team: Information about what the role encompasses would have been useful, because the role can be daunting initially. Training and preparing the future pharmacist workforce for general practice roles were also suggested as a way to assist integration. Respondents believed this could extend to providing on-going, dedicated education and training, and incorporating practice pharmacists in a career progression framework.
Many pharmacists commented that the role was very rewarding, and provided an opportunity to develop their niche expertise in medicines management. For some, becoming pharmacist prescribers enabled them to be more eff ective in their existing role; for example, undertaking repeat prescribing allowed pharmacist identifi cation of patients who would benefi t from their input and medicines optimisation. Pharmacists felt that their role benefi ted patients, especially patients from high-needs populations, freed up GP time and helped answer community pharmacists questions.
Having greater access to patients' clinical notes was reported as hugely benefi cial. One former community pharmacist found that working in general practice highlighted the paucity of patient information available to community pharmacists, limiting the level of care that can be provided:
Th is is especially important if we are expecting community pharmacists to provide more clinical services in primary care. From experience, you can't apply the knowledge you have without knowing the health issues that aff ect a particular patient . (R10)
Working in general practice allowed pharmacists to take a more integrative approach to health care delivery, which facilitated increased uptake of pharmacist recommendations to GPs and promoted the role of pharmacists. Some respondents felt isolated from their pharmacist colleagues and, apart from one who received clinical supervision, there was a lack of professional support, including from peers. For some pharmacists, working across multiple practices made it diffi cult to build rapport and trust with individual practice teams.
Many respondents emphasised the need for more practice pharmacists in order to meet an unmet need, which respondents believed is currently unrecognised by many GPs. Some respondents commented that the costs of employing practice pharmacists are more than off set by the diff erences made to the wellbeing of patients and cost savings to DHBs.
Discussion
Th is study aimed to understand pharmacist integration into general practice, with results highlighting that the role is not yet widespread.
Hawke's Bay DHB has pioneered pharmacists working in this setting, with unsustainable growth in medicine volumes and costs leading to a decision to fund two pharmacists in general practice in 2011. 31 In Year 2, a reduction in medicine costs of 10.8% with NZ$848000 in savings was attributed to the impact of the practice pharmacists, equating to a 4:1 return on investment. 31 If the savings attributed to the Hawke's Bay practice pharmacists were replicated across DHBs nationally, the potential economic benefi ts to the health system are signifi cant.
All but one responding pharmacist held clinical pharmacy postgraduate qualifi cations, and 81% of respondents were at least 10 years post-registration: some respondents highlighted having career experience as a specifi c role facilitator. Th ese fi ndings suggest that the practice pharmacist role in NZ suits pharmacists with postgraduate clinical qualifi cations and prior experience of practicing as a pharmacist. PHOs were the most common employer of responding practice pharmacists but the funding sources for the positions were evenly split between DHBs and PHOs. Th e implication is that PHOs may have contracts with, and receive funding from, DHBs to employ pharmacists across their practices. It is important to determine economically viable funding models that ensure ongoing sustainability for the role, because a lack of secure funding was highlighted as a major barrier to increasing the number of pharmacists working in general practice.
Many respondents' time was split across multiple practices, and for some this was considered a barrier to building rapport and trust with practice staff . Time spent in a practice has been reported to infl uence the types of roles held, with full-time practice pharmacists typically taking on more roles than parttime pharmacists. 35 In the evaluation of the English pilot scheme, one of the biggest problems raised in the scheme was pharmacists working part-time. 40 Th e roles that respondents hold focus strongly on direct patient care, with supplementary roles designed to improve practice effi ciencies and the eff ectiveness of other clinicians. Th ese fi ndings align with reports from Australia, Canada and England, 34 , 35 , 41 although pharmacist prescribing in general practice occurs at much higher levels in England, where a prescribing qualifi cation is mandatory and prescribing is recognised as a core role of practice pharmacists. 42 , 43 Factors aff ecting the slow uptake of pharmacist prescribing in NZ are multifaceted, but may include a lack of funding for continuing education opportunities, an absence of established roles in practice and resistance from other health professionals. 44 Much like the UK, 23 current trends in the NZ primary care workforce point towards a need for more resources to meet the increased health care demands facing general practice. 20 Placing more pharmacists in general practice, particularly those who can prescribe, may help to meet these needs.
Tasks not typically performed by respondents included clinical oversight of practice nurses, creating and managing standing orders, providing medicines education groups for patients and ordering or scheduling laboratory tests. Th ese tasks could be perceived as the traditional responsibility of other practice staff , or perhaps are not provided by the practices in our study. Th ese lower rates in NZ could also possibly refl ect issues of role encroachment. 45 -47 However, research consistently highlights the initial reservations of practice staff dissipate over time, and the pharmacist becomes an integral part of the multidisciplinary team. 48 -51 Some of our respondents also mentioned this. It is important that general practice pharmacists are given time and opportunity to build rapport and relationships with practice staff , and to demonstrate how they can add value to patient care and the overall running of practices. Th e evaluation of the English pilot scheme found that GPs are unlikely to realise the benefi ts of having a pharmacist embedded within the practice until aft er the fi rst year of integration. 40 Respondents felt that working in general practice had positively infl uenced various aspects of their practice. In particular, job satisfaction increased or greatly increased for 94% of respondents. For pharmacists coming from a hospital background, this may refl ect more meaningful longer-term personal interactions and relationships with patients. For community pharmacists, this may arise from making better use of their knowledge and expertise regarding medicines. Th is is supported by reports of job satisfaction for pharmacists being positively linked with the J OURNAL OF PRIMARY HEALTH CARE 167 degree to which cognitive and clinical activities are performed.
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Strengths and limitations
Th is study used a comprehensive recruitment strategy to describe the characteristics of practice pharmacists in NZ. It therefore provides baseline data allowing developments in this area to be monitored.
Not every pharmacist working in general practice completed the questionnaire, so the study's representation of practice pharmacists is incomplete.
Although the free-text responses generated some consistent themes, a small number of pharmacists contributed most of the free-text data, so these fi ndings may not be generalisable to all general practice pharmacists.
Implications
Further research that seeks to explore the views of patients and other health-care professionals, and compares and contrasts diff erent models of pharmacist integration into general practice, may provide insights to ensure further integration occurs effi ciently and achieves maximum benefi ts for all parties involved. When pharmacists apply for their Annual Practicing Certifi cate, they have the opportunity to select their type of work, but currently there is no 'general practice' option. Th e Pharmacy Council should consider adding an option for this group of pharmacists, so that their numbers can be accurately reported and monitored over time.
Th e results highlight the value of having guidelines to describe the role. Clarity around practice pharmacists' scope of practice would be useful to allow GPs to have a clear understanding about how a pharmacist may fi t within their practice. A code of practice is currently under development by the Pharmacy Council, 55 and this should be a useful tool for both practices and pharmacists moving forward. Eff orts to formalise ongoing education, training and support for practice pharmacists should also be considered.
Conclusion
Th is research describes the current landscape of pharmacist integration into general practice in NZ. Th e fi ndings are consistent with previous reports suggesting the role has been taken up more in particular regions of the country. Pharmacists in these roles tend to be experienced and have completed postgraduate study. Th e role has facilitated improved communication and rapport with GPs, interdisciplinary collaboration, application of pharmaceutical knowledge and job satisfaction. Barriers to integration included system-level diffi culties around funding and a lack of understanding about the skill and knowledge set of pharmacists. Overcoming these will be important for role expansion as NZ seeks to achieve the aims of the New Zealand Health Strategy and Pharmacy Action Plan.
